Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: Results of a multicenter, randomized, double-blind, active drug-controlled study

Arthritis and Rheumatism

Volumn 58, Issue 7, 2008, Pages 1921-1930

  Weinblatt, Michael E ^a   Schiff, Michael H ^b   Ruderman, Eric M ^c   Bingham III, Clifton O ^d   Li, Juan ^e,f   Louie, James ^e,f   Furst, Daniel E ^e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; C REACTIVE PROTEIN; ETANERCEPT; METHOTREXATE; PLACEBO; RHEUMATOID FACTOR;

ADULT; ANXIETY; ARTICLE; BILE DUCT OBSTRUCTION; BRONCHITIS; CELLULITIS; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GASTRITIS; HEART INFARCTION; HUMAN; IMMOBILIZATION SYNDROME; INFECTIOUS ARTHRITIS; INJECTION SITE REACTION; LACERATION; LOBAR PNEUMONIA; LYMPHANGITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; OPPORTUNISTIC INFECTION; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; PELVIS FRACTURE; PLEURA EFFUSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SEPSIS; SEX DIFFERENCE; SIDE EFFECT; SINUSITIS; SKIN LACERATION; SKIN MANIFESTATION; STATISTICAL SIGNIFICANCE; SYNDROME; THORAX PAIN; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; VISUAL ANALOG SCALE;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; METHOTREXATE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME;

EID: 47249094097     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23493     Document Type: Article

References (32)

1. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999;130: 478-86.
2. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340:253-9.
3. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81.
4. Van Riel PL, Taggart AJ, Sany J, Gaubitz M, Nab HW, Pedersen R, et al. Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study. Ann Rheum Dis 2006;65:1478-83.
5. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343:1586-93.
6. Enbrel (etanercept) prescribing information. Thousand Oaks (CA): Immunex Corporation; 2006.
7. Johnsen AK, Schiff MH, Mease PJ, Moreland LW, Maier AL, Coblyn JS, et al. Comparison of 2 doses of etanercept (50 vs 100 mg) in active rheumatoid arthritis: a randomized double blind study. J Rheumatol 2006;33:659-64.
8. Van Gestel AM, Anderson JJ, van Riel PL, Boers M, Haagsma CJ, Rich B, et al. ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. J Rheumatol 1999;26:705-11.
9. Prevoo ML, van Gestel AM, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. Br J Rheumatol 1996;35:1101-5.
10. Van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998;41:1845-50.
11. Van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996;39:34-40.
12. Drummond MF, O'Brien B, Stoddart G, Torrence G. Cost-utility analysis. In: Methods for the economic evaluation of health care programmes. 2nd ed. Oxford: Oxford University Press; 1997. p. 160-3.
13. Brooks R. EuroQol: the current state of play. Health Policy 1996;37:53-72.
14. Hurst NP, Jobanputra P, Hunter M, Lambert M, Lochhead A, Brown H, the Economic and Health Outcomes Research Group. Validity of Euroqol - a generic health status instrument - in patients with rheumatoid arthritis. Br J Rheumatol 1994;33:655-62.
15. Boonen A, van der Heijde D, Landewe R, van Tubergen A, Mielants H, Dougados M, et al. How do the EQ-5D, SF-6D and the well-being rating scale compare in patients with ankylosing spondylitis? Ann Rheum Dis 2007;66:771-7.
16. Clopper C, Pearson S. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934;26:404-13.
17. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003;349:2014-22.
18. Gordon KB, Gottlieb AB, Leonardi CL, Elewski BE, Wang A, Jahreis A, et al. Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy. J Dermatolog Treat 2006;17:9-17.
19. Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CE, Nakanishi AM, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005;152:1304-12.
20. Rahman MU, Strusberg I, Geusens P, Berman A, Yocum D, Baker D, et al. Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66: 1233-8.
21. Finckh A, Simard JF, Gabay C, Guerne PA. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. Ann Rheum Dis 2006;65:746-52.
22. Etemad L, Yu EB, Wanke LA. Dose adjustment over time of etanercept and infliximab in patients with rheumatoid arthritis. Manag Care Interface 2005;18:21-7.
23. Durez P, Van den Bosch F, Corluy L, Veys EM, De Clerck L, Peretz A, et al. A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study. Rheumatology (Oxford) 2005;44:465-8.
24. Berger A, Edelsberg J, Li TT, Maclean JR, Oster G. Dose intensification with infliximab in patients with rheumatoid arthritis. Ann Pharmacother 2005;39:2021-5.
25. Sfern R, Wolfe F. Infliximab dose and clinical status: results of 2 studies in 1642 patients with rheumatoid arthritis. J Rheumatol 2004;31:1538-45.
26. Gilbert TD Jr, Smith D, Ollendorf DA. Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskelet Disord 2004;5:36.
27. Haraoui B, Cameron L, Ouellet M, White B. Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response. J Rheumatol 2006;33:31-6.
28. Ariza-Ariza R, Navarro-Sarabia F, Hernandez-Cruz B, Rodriguez-Arboleya L, Navarro-Compan V, Toyos J. Dose escalation of the anti-TNF-α agents in patients with rheumatoid arthritis: a systematic review. Rheumatology (Oxford) 2007;46:529-32.
29. Gomez-Reino JJ, Carmona L. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 2006;8:R29.
30. Wick MC, Ernestam S, Lindblad S, Bratt J, Klareskog L, van Vollenhoven RF. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital. Scand J Rheumatol 2005;34:353-8.
31. Van Vollenhoven RF. Switching between biological agents. Clin Exp Rheumatol 2004;22(Suppl 35):S115-21.
32. Van Vollenhoven R, Harju A, Brannemark S, Klareskog L. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor α blockers can make sense. Ann Rheum Dis 2003;62:1195-8.